Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph early_phase_1
1
8%
Ph not_applicable
1
8%
Ph phase_1
5
42%
Ph phase_2
5
42%

Phase Distribution

6

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
5(41.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(8)
Terminated(3)

Detailed Status

Completed8
Withdrawn2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (8.3%)
Phase 15 (41.7%)
Phase 25 (41.7%)
N/A1 (8.3%)

Trials by Status

withdrawn217%
not_yet_recruiting18%
completed867%
terminated18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_1

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

NCT01737502
not_yet_recruitingphase_2

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

NCT06805656
terminatedphase_2

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

NCT03456700
completedphase_2

Auranofin for Giardia Protozoa

NCT02736968
completedphase_1

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

NCT02770378
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01737502Phase 1

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Completed
NCT06805656Phase 2

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not Yet Recruiting
NCT03456700Phase 2

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Terminated
NCT02736968Phase 2

Auranofin for Giardia Protozoa

Completed
NCT02770378Phase 1

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed
NCT02961829Not Applicable

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed
NCT01747798Early Phase 1

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
NCT02063698Phase 2

Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome

Completed
NCT02089048Phase 1

Auranofin PK Following Oral Dose Administration

Completed
NCT02126527Phase 1

Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer

Withdrawn
NCT01419691Phase 2

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Completed
NCT02176135Phase 1

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12